AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1515386 — intervention group
Group type: COMPARATOR
Intervention: 17.5 ml bupivacaine
Number of subjects: 16
Study 6365194 — intervention group
Group type: EXPERIMENTAL
Intervention: QU.A.RT. method (quadrantectomy, axillary dissection, radiotherapy)
Number of subjects: 0
Study 6365194 — intervention group
Group type: COMPARATOR
Intervention: Halsted mastectomy
Number of subjects: 0
Study 30027597 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Plane Guidance (IPFA)
Number of subjects: 18
Study 30027597 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic Needle Tracking (ENT)
Number of subjects: 18
Study 30027597 — intervention group
Group type: COMPARATOR
Intervention: Freehand
Number of subjects: 18
Study 30498351 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-monthly paliperidone palmitate (PP3M)
Number of subjects: 0
Study 30498351 — intervention group
Group type: COMPARATOR
Intervention: once-monthly paliperidone palmitate (PP1M)
Number of subjects: 0
Study 26845640 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted peer-group based intervention including FP communication skills training, antibiotic prescribing agreements, and quarterly feedback figures.
Number of subjects: 8
Study 26845640 — intervention group
Group type: COMPARATOR
Intervention: Control group (matched PTAM groups).
Number of subjects: 8
Study 24552366 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet (45-50% carbohydrate, 30-35% fat, 15-20% protein)
Number of subjects: 104
Study 24552366 — intervention group
Group type: COMPARATOR
Intervention: Conventional Chinese diet (55-60% carbohydrate, 25-30% fat, 10-15% protein)
Number of subjects: 104
Study 22152974 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified N-terminal brain natriuretic peptide-guided HF therapy
Number of subjects: 566
Study 22152974 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 566
Study 19129205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 300 mg/day
Number of subjects: 214
Study 19129205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg/day
Number of subjects: 214
Study 19129205 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 900 mg/day
Number of subjects: 214
Study 19129205 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 214
Study 17453362 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated chemotherapy (de FEC)
Number of subjects: 129
Study 17453362 — intervention group
Group type: COMPARATOR
Intervention: FEC and HDCT+BMS
Number of subjects: 129
Study 15610835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 1, men)
Number of subjects: 83
Study 15610835 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 microg/kg and thiopental 3 mg/kg (Group 2, women)
Number of subjects: 83
Study 15610835 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl 1.5 microg/kg and thiopental 2 mg/kg (Group 3, women)
Number of subjects: 83
Study 15610835 — intervention group
Group type: COMPARATOR
Intervention: Baseline values
Number of subjects: 83
Study 11594574 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 0
Study 9701719 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 x 50 microgram TRH administered intravenously at 22.00, 23.00, 24.00, and 01.00 h
Number of subjects: 7
Study 9701719 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered intravenously
Number of subjects: 7
Study 8053243 — intervention group
Group type: EXPERIMENTAL
Intervention: VVI-R pacing
Number of subjects: 27
Study 2686604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to alter triglyceride levels
Number of subjects: 0
Study 31356512 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip Extension Exercise (HEE)
Number of subjects: 24
Study 31356512 — intervention group
Group type: COMPARATOR
Intervention: Nordic Hamstring Exercise (NHE)
Number of subjects: 24
Study 30596450 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory training (Study 1)
Number of subjects: 41
Study 30596450 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal working memory training (Study 2)
Number of subjects: 41
Study 30596450 — intervention group
Group type: COMPARATOR
Intervention: Active control group (Study 1)
Number of subjects: 41
Study 30596450 — intervention group
Group type: COMPARATOR
Intervention: Active control group (Study 2)
Number of subjects: 41
Study 31585343 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week internet-delivered exposure therapy
Number of subjects: 140
Study 31585343 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 140
Study 27998910 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Number of subjects: 55
Study 27998910 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 55
Study 27998910 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 55
Study 25441960 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Stop Light Diet (eSLD)
Number of subjects: 20
Study 25441960 — intervention group
Group type: COMPARATOR
Intervention: Conventional Diet (CD)
Number of subjects: 20
Study 25441960 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer usage
Number of subjects: 20
Study 23550808 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg dehydroepiandrosterone (DHEA) added to EE/DRSP COC
Number of subjects: 0
Study 23550808 — intervention group
Group type: COMPARATOR
Intervention: Placebo (without DHEA) in EE/DRSP COC
Number of subjects: 0
Study 21166602 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir/ritonavir (ATV/r)
Number of subjects: 83
Study 21166602 — intervention group
Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r)
Number of subjects: 83
Study 19623023 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR)
Number of subjects: 24
Study 19623023 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA)
Number of subjects: 24
Study 16687697 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe water systems (SWS)
Number of subjects: 196
Study 16687697 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of SWS
Number of subjects: 196
Study 16687697 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical scenario based on another SWS trial in Kenya
Number of subjects: 196
Study 12600797 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac-K 12.5mg
Number of subjects: 620
Study 12600797 — intervention group
Group type: EXPERIMENTAL
Intervention: diclofenac-K 25mg
Number of subjects: 620
Study 12600797 — intervention group
Group type: EXPERIMENTAL
Intervention: ibuprofen 400mg
Number of subjects: 620
Study 12600797 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 620
Study 10929920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 10 mg BID
Number of subjects: 714
Study 10929920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 5 mg BID
Number of subjects: 714
Study 10929920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 20 mg BID
Number of subjects: 714
Study 10929920 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast 40 mg BID
Number of subjects: 714
Study 10929920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 714
Study 8644030 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists (nifedipine, verapamil, diltiazem)
Number of subjects: 160
Study 8644030 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 160
Study 8644030 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment efficacy
Number of subjects: 160
Study 8644030 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonists treatment
Number of subjects: 160
Study 1455885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholangiography
Number of subjects: 115
Study 1455885 — intervention group
Group type: COMPARATOR
Intervention: No cholangiography (Control)
Number of subjects: 115
Study 3901672 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 30 mg
Number of subjects: 40
Study 3901672 — intervention group
Group type: EXPERIMENTAL
Intervention: clonidine 0.150 mg
Number of subjects: 40
Study 3901672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 30859984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 441mg
Number of subjects: 432
Study 30859984 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole Lauroxil 882mg
Number of subjects: 432
Study 30836809 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency airborne ultrasound therapy (Glybetac)
Number of subjects: 58
Study 30836809 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 58
Study 27717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative goal-setting intervention using a low‐literacy aid
Number of subjects: 302
Study 27717532 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-driven action plans
Number of subjects: 302
Study 26413529 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression group (n = 29)
Number of subjects: 59
Study 26413529 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 30)
Number of subjects: 59
Study 23430026 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotomy group
Number of subjects: 320
Study 23430026 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 320
Study 21457793 — intervention group
Group type: EXPERIMENTAL
Intervention: PVAC group (duty-cycled bipolar and unipolar radiofrequency)
Number of subjects: 80
Study 21457793 — intervention group
Group type: COMPARATOR
Intervention: 3D group (point-by-point ablation)
Number of subjects: 80
Study 18835735 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 17beta‐oestradiol valerate 2mg twice daily
Number of subjects: 12
Study 18835735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17943521 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm minimisation intervention
Number of subjects: 4636
Study 17943521 — intervention group
Group type: COMPARATOR
Intervention: Standard abstinence-based intervention
Number of subjects: 4636
Study 15230858 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha nl after prednisolone priming
Number of subjects: 210
Study 15230858 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-alpha 2a
Number of subjects: 210
Study 15230858 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 210
Study 14745340 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacine
Number of subjects: 275
Study 14745340 — intervention group
Group type: COMPARATOR
Intervention: Comparer antibiotics (amoxicillin-clavulanic acid, amoxicillin, ceftriaxone, ceftriaxone plus cefuroxime +/- erythromycin)
Number of subjects: 275
Study 14745340 — intervention group
Group type: COMPARATOR
Intervention: Comparer antibiotics
Number of subjects: 275
Study 9696721 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine (30 g/day)
Number of subjects: 10
Study 9696721 — intervention group
Group type: COMPARATOR
Intervention: glycine (13 g/day; placebo)
Number of subjects: 10
Study 8026089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenoidectomy
Number of subjects: 222
Study 8026089 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 222
Study 8026089 — intervention group
Group type: EXPERIMENTAL
Intervention: Age at operation
Number of subjects: 222
Study 8026089 — intervention group
Group type: EXPERIMENTAL
Intervention: History of earache prior to operation
Number of subjects: 222
Study 8026089 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental smoking habits
Number of subjects: 222
Study 2626417 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-part intervention (lecture, chart-based reminder, biweekly feedback)
Number of subjects: 36
Study 2626417 — intervention group
Group type: COMPARATOR
Intervention: Control groups (Group II and Group III)
Number of subjects: 36
Study 30738593 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation using perfluorooctyl bromide
Number of subjects: 0
Study 28139023 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 25
Study 28139023 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg
Number of subjects: 25
Study 28139023 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg
Number of subjects: 25
Study 26167739 — intervention group
Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 0
Study 26167739 — intervention group
Group type: COMPARATOR
Intervention: Sham Reiki
Number of subjects: 0
Study 23052568 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden
Number of subjects: 0
Study 23052568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Number of subjects: 0
Study 23052568 — intervention group
Group type: EXPERIMENTAL
Intervention: Biperiden + Rivastigmine
Number of subjects: 0
Study 22125782 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of prednisolone daily for 14 days
Number of subjects: 109
Study 22125782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 19095857 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot spinal (SSS) anesthesia
Number of subjects: 30
Study 19095857 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined spinal-epidural (CSE) anesthesia
Number of subjects: 30
Study 16229022 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong treatment group (n = 32)
Number of subjects: 56
Study 16229022 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving no additional intervention (n = 24)
Number of subjects: 56
Study 15526246 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 400 mg daily plus irbesartan 300 mg daily
Number of subjects: 90
Study 15526246 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone 400 mg daily plus irbesartan 150 mg daily
Number of subjects: 90
Study 15526246 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone 400 mg daily
Number of subjects: 90
Study 11139948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide (PLS) 100-150 mg single oral dose
Number of subjects: 72
Study 11139948 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (DISO) 2 mg/kg infusion (maximum dose = 100 mg)
Number of subjects: 72
Study 11139948 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilsicainide (PLS)
Number of subjects: 72
Study 11139948 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide (DISO)
Number of subjects: 72
Study 9313630 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulodexide (administered IM for ten days and orally for fifty days)
Number of subjects: 30
Study 9313630 — intervention group
Group type: COMPARATOR
Intervention: Calcium Heparin (subcutaneous for sixty days)
Number of subjects: 30
Study 8398303 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus recombinant interferon‐alfa2a (IFN)
Number of subjects: 152
Study 8398303 — intervention group
Group type: COMPARATOR
Intervention: DTIC alone
Number of subjects: 152
Study 7039840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinoxacin 250 mg, four times a day
Number of subjects: 58
Study 7039840 — intervention group
Group type: COMPARATOR
Intervention: Nitrofurantoin 100 mg, four times a day
Number of subjects: 58
Study 30781485 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g of flavanol‐rich cocoa powder ingested with a diabetic‐suitable breakfast
Number of subjects: 12
Study 30781485 — intervention group
Group type: COMPARATOR
Intervention: Microcrystalline cellulose ingested with a diabetic‐suitable breakfast
Number of subjects: 12
Study 27434189 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (TUS)
Number of subjects: 20
Study 27434189 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 20
Study 26174294 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol at an estimated brain concentration of 0.90 μg ml(‐1)
Number of subjects: 35
Study 26174294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24450487 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended combined oral contraceptives
Number of subjects: 0
Study 24450487 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Number of subjects: 0
Study 24450487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22803758 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical reflection guidelines
Number of subjects: 149
Study 22803758 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback on both content and reflective ability
Number of subjects: 149
Study 22803758 — intervention group
Group type: COMPARATOR
Intervention: Definition of critical reflection only
Number of subjects: 149
Study 19443528 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 500 microg
Number of subjects: 6184
Study 19443528 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol (SAL) 50 microg
Number of subjects: 6184
Study 19443528 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (SFC)
Number of subjects: 6184
Study 19443528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6184
Study 17479928 — intervention group
Group type: EXPERIMENTAL
Intervention: Actions presented with varying distance from a routine
Number of subjects: 0
Study 16494979 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional knee bracing
Number of subjects: 30
Study 16494979 — intervention group
Group type: COMPARATOR
Intervention: No bracing
Number of subjects: 30
Study 12644803 — intervention group
Group type: EXPERIMENTAL
Intervention: D‐DBA technique (DBA applied immediately after preparations)
Number of subjects: 120
Study 12644803 — intervention group
Group type: EXPERIMENTAL
Intervention: I‐DBA technique (DBA applied just before luting)
Number of subjects: 120
Study 12644803 — intervention group
Group type: COMPARATOR
Intervention: No DBA technique (no bonding agent used)
Number of subjects: 120
Study 10471420 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CE)
Number of subjects: 1415
Study 10471420 — intervention group
Group type: COMPARATOR
Intervention: Medical care alone
Number of subjects: 1415
Study 7570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3-4 times a week for 6 weeks, 20-30 minutes per session)
Number of subjects: 45
Study 7570509 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard rehabilitation therapy)
Number of subjects: 45
Study 7570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment
Number of subjects: 45
Study 1937998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg
Number of subjects: 28
Study 1937998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 28
Study 1937998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 600 mg
Number of subjects: 28
Study 1937998 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol (all doses)
Number of subjects: 28
Study 1937998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6130532 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (0.4 or 0.8 mg subcutaneous injections)
Number of subjects: 0
Study 6130532 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol (2.5 mg)
Number of subjects: 0
Study 6130532 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 6130532 — intervention group
Group type: EXPERIMENTAL
Intervention: 16,16-dimethyl prostaglandin E2 (DmPGE2, 7 to 140 ng/kg intravenous over five minutes)
Number of subjects: 0
Study 31296475 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention group
Number of subjects: 0
Study 31296475 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education group
Number of subjects: 0
Study 31296475 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29023535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte solution (CES, 6% carbohydrate)
Number of subjects: 11
Study 29023535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte‐protein solution (CEPS, 2% protein plus 4% carbohydrate)
Number of subjects: 11
Study 29023535 — intervention group
Group type: COMPARATOR
Intervention: Noncaloric sweetened placebo (PLA)
Number of subjects: 11
Study 29023535 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate‐electrolyte‐protein solution (CEPS)
Number of subjects: 11
Study 26234894 — intervention group
Group type: EXPERIMENTAL
Intervention: Two minutes CPR
Number of subjects: 119
Study 26234894 — intervention group
Group type: COMPARATOR
Intervention: Five cycles CPR (30:2)
Number of subjects: 119
Study 23782555 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO 150 IU/kg body weight
Number of subjects: 150
Study 23782555 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21452945 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-generated action effects
Number of subjects: 0
Study 21452945 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent effect priming
Number of subjects: 0
Study 21452945 — intervention group
Group type: COMPARATOR
Intervention: Incongruent or neutral effect stimuli
Number of subjects: 0
Study 19770662 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrograde autologous priming (RAP)
Number of subjects: 120
Study 19770662 — intervention group
Group type: COMPARATOR
Intervention: Standard priming
Number of subjects: 120
Study 19770662 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP
Number of subjects: 120
Study 17057609 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF + FTC + EFV
Number of subjects: 517
Study 17057609 — intervention group
Group type: COMPARATOR
Intervention: ZDV/3TC + EFV
Number of subjects: 517
Study 12960117 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg EGCG once/day
Number of subjects: 40
Study 12960117 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg EGCG twice/day
Number of subjects: 40
Study 12960117 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg EGCG as Polyphenon E once/day
Number of subjects: 40
Study 12960117 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg EGCG as Polyphenon E twice/day
Number of subjects: 40